首页> 外文OA文献 >p53-Associated Parkin-like cytoplasmic protein (Parc) short-interfering RNA (siRNA) alters p53 location and biology of Peyronie's disease fibroblasts
【2h】

p53-Associated Parkin-like cytoplasmic protein (Parc) short-interfering RNA (siRNA) alters p53 location and biology of Peyronie's disease fibroblasts

机译:p53关联的帕金样细胞质蛋白(Parc)短干扰RNA(siRNA)改变了Peyronie病成纤维细胞的p53定位和生物学

摘要

OBJECTIVE • To evaluate the impact of p53-associated Parkin-like cytoplasmic protein (Parc) short-interfering RNA (siRNA) on the location of p53 as well as the biology of Peyronie's disease (PD) plaque-derived fibroblasts after Parc knockdown. PATIENTS AND METHODS • Plaque tissue was excised from men with stable PD undergoing penile reconstructive surgery and used to produce cultured PD plaque-derived fibroblasts. • Immunofluorescence (IF) and reverse transcription-polymerase chain reaction (RT-PCR) were then used to define the location of p53 and Parc before and after siRNA. • Nuclear fractionation studies were used to assess the chronology of translocation of p53 from cytoplasm to nucleus on Parc knockdown. • The terminal transferase dUTP Nick end labelling (TUNEL) assay was used to assess the apoptotic indices of the PD fibroblasts after Parc knockdown. RESULTS • IF and PCR showed high cytoplasmic levels of p53 and Parc before siRNA. On IF, there was little or no p53 present within the nucleus before Parc knockdown. • After Parc siRNA, IF showed translocation of p53 to the fibroblast nucleus, while Parc levels dropped significantly, but what Parc remained was confined to the cytoplasm with none present in the nucleus. • Nuclear fractionation studies using RT-PCR confirmed this translocation phenomenon and showed the chronology of the event. All p53 had moved from the cytoplasm to the nucleus within 16 h of Parc siRNA. • On TUNEL assay, apoptotic indices increased dramatically after Parc siRNA. CONCLUSIONS • These data prove that Parc is a cytoplasmic anchor for p53 in PD plaque-derived fibroblasts and may be the primary cause of the stabilization and defunctionalization of p53 in these cells. • These findings support Parc as a novel target for PD pharmacotherapy, perhaps using human siRNA technologies once commercially available.ud© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.
机译:目的•评估p53敲除后与p53相关的帕金样细胞质蛋白(Parc)短干扰RNA(siRNA)对p53位置以及佩隆尼氏病(PD)斑块成纤维细胞生物学的影响。病人和方法•从接受过阴茎重建手术的稳定PD的男性中切除韧带组织,并将其用于培养培养的PD斑块成纤维细胞。 •然后使用免疫荧光(IF)和逆转录聚合酶链反应(RT-PCR)来确定siRNA前后p53和Parc的位置。 •核分离研究用于评估Parc击倒后p53从细胞质到细胞核移位的时间顺序。 •末端转移酶dUTP缺口末端标记法(TUNEL)用于评估Parc敲低后PD成纤维细胞的凋亡指数。结果•IF和PCR显示siRNA之前p53和Parc的细胞质水平很高。在IF上,在Parc敲低之前,核内几乎没有p53。 •在Parc siRNA后,IF显示p53易位至成纤维细胞核,而Parc的水平显着下降,但Parc所保留的仅局限于细胞质,细胞核中不存在。 •使用RT-PCR的核分级分离研究证实了这种易位现象,并显示了事件发生的时间顺序。在Parc siRNA的16小时内,所有p53均已从细胞质移至细胞核。 •在TUNEL分析中,Parc siRNA后凋亡指数急剧增加。结论•这些数据证明Parc是PD斑块成纤维细胞中p53的细胞质锚,可能是这些细胞中p53稳定和失功能的主要原因。 •这些发现支持Parc作为PD药物治疗的新靶标,也许可以使用市售的人siRNA技术。 ud©2010,作者。北京国际大学©2010北京国际大学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号